SCHEMBL23218237

SCHEMBL23218237

CCOC(=O)Cc1ccc(Br)cc1OCc1coc2ccc(-c3cccc(CNC(=O)OC(C)(C)C)c3)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.36
BRD4 O60885 2/20 0.34
CREBBP Q92793 1/20 0.34
PFKFB3 Q16875 1/20 0.33
CASP1 P29466 1/20 0.33
EGFR P00533 1/20 0.33
RAF1 P04049 1/20 0.33
KDR P35968 1/20 0.33
MAP2K2 P36507 1/20 0.33
MAP2K1 Q02750 1/20 0.33
AURKB Q96GD4 1/20 0.33
HDAC1 Q13547 1/20 0.33
CFD P00746 1/20 0.33
GLS O94925 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PSMB5 P28074 1/20 0.32
RXRA P19793 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852677 1.00 TP53 (0.36) TP53BRD4CREBBPPFKFB3CASP1
SCHEMBL23218162 0.91 GRM2 (0.36) TP53BRD4CREBBPCASP1HDAC1
SCHEMBL29852557 0.91 GRM2 (0.36) TP53BRD4CREBBPCASP1HDAC1
SCHEMBL29853071 0.89 BRD4 (0.35) TP53BRD4CREBBPCASP1HDAC1
SCHEMBL23218268 0.89 BRD4 (0.35) TP53BRD4CREBBPCASP1HDAC1
SCHEMBL23218473 0.88 TP53 (0.35) TP53BRD4CREBBPPFKFB3CASP1
SCHEMBL29852424 0.88 TP53 (0.35) TP53BRD4CREBBPPFKFB3CASP1
SCHEMBL23218260 0.85 CFD (0.44) PFKFB3CFDMAOAMAOBMAPT
SCHEMBL29853215 0.85 CFD (0.44) PFKFB3CFDMAOAMAOBMAPT
SCHEMBL23218400 0.83 TP53 (0.42) TP53BRD4CREBBPCASP1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TP53 3891/4885BRD4 3880/4885CREBBP 3711/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TP53 3580/4885BRD4 4824/4885CREBBP 3598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.